

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY
04 APR 19**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Ropes & Gray			
2. Address <input checked="" type="checkbox"/> Check if different than previously reported One Metro Center 700 12th St. NW, Suite 900			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20005			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Thomas M. Susman	(202) 508-4620	tsusman@ropesgray.com	33682
7. Client Name <input type="checkbox"/> Self Novartis Pharmaceuticals Corporation			6. House ID # 30721

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31) 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more ⇒ \$ 20,000.00
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more ⇒ \$ _____
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of

- Method A.** Reporting amounts using LDA definition
- Method B.** Reporting amounts under section 603 Internal Revenue Code
- Method C.** Reporting amounts under section 162 Internal Revenue Code

Signature _____

Printed Name and Title _____

LD-2 (REV. 6/98)

P

Registrant Name Ropes & Gray Client Name Novartis Pharmaceuticals Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the r engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for oral anti-cancer therapies.
H.R. 1288; S. 1037

Medicare Prescription Drug and Modernization Act of 2003 (H.R. 1, S. 1)

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sam Turner, Partner	
Elizabeth Goss, Partner	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature 

Date 1/30/04

Signature _____

Printed Name and Title Thomas M. Susman, Partner

Form LD-2 (Rev. 6/98)

Page _